Vireo Growth Q1 FY26 net loss widens to $20.3 million; revenue triples to $106.2 million
- Vireo Growth posted revenue of USD 106.2 million for quarter ended March 31, 2026, up 333%, while net loss widened to USD 20.3 million.
- Gross profit rose to USD 59.3 million, lifting gross margin to 55.8% from 50.6%.
- Operating income increased to USD 9 million, while total other expense climbed to USD 13.2 million due to a USD 5.5 million loss from remeasurement of contingent consideration.
- Adjusted EBITDA rose to USD 32.7 million, while operating revenue spanned eight states with retail sales coming from 82 dispensaries.
- Completed acquisition of a controlling interest in Vireo Health of Rocky Mountain on March 19, 2026, adding 45 dispensaries and two manufacturing facilities in Colorado and New Mexico through Schwazze restructuring transaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vireo Growth Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-059455), on May 12, 2026, and is solely responsible for the information contained therein.
